Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cartesian Therapeutics Inc shares valued at $508,751 were purchased by SPRINGER TIMOTHY A on Apr 10 ’25. At $10.47 per share, SPRINGER TIMOTHY A acquired 48,595 shares. The insider’s holdings grew to 620,175 shares worth approximately $6.95 million following the completion of this transaction.
Also, SPRINGER TIMOTHY A purchased 41,782 shares, netting a total of over 393,947 in proceeds. Following the buying of shares at $9.43 each, the insider now holds 571,580 shares.
Before that, SPRINGER TIMOTHY A had added 36,338 shares to its account. In a trade valued at $391,455, the Director bought Cartesian Therapeutics Inc shares for $10.77 each. Upon closing the transaction, the insider’s holdings increased to 36,338 shares, worth approximately $7.36 million.
As published in their initiating research note from BTIG Research on December 19, 2024, Cartesian Therapeutics Inc [RNAC] has been a Buy and the price target has been revised to $42. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early August. As of July 02, 2024, Oppenheimer has decreased its “an Outperform” rating to a “Perform” for RNAC. Earlier on June 04, 2024, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for RNAC stock.
Analyzing RNAC Stock Performance
On last trading session, Cartesian Therapeutics Inc [NASDAQ: RNAC] plunged -1.41% to $11.21. During the last five days, there has been a drop of approximately -2.18%. Over the course of the year, Cartesian Therapeutics Inc shares have dropped approximately -53.81%. Shares of the company reached a 52-week high of $20.12 on 01/16/25 and a 52-week low of $8.46 on 05/27/25.
Support And Resistance Levels for Cartesian Therapeutics Inc (RNAC)
According to the 24-hour chart, there is a support level at 10.93, which, if violated, would cause prices to drop to 10.65. In the upper region, resistance lies at 11.51. The next price resistance is at 11.80. RSI (Relative Strength Index) is 56.38 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Cartesian Therapeutics Inc (RNAC)?
In terms of Cartesian Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 43 in the next 12 months, up nearly 278.19% from the previous closing price of $11.37. Analysts anticipate Cartesian Therapeutics Inc stock to reach 45 by 2025, with the lowest price target being 40. In spite of this, 0 analysts ranked Cartesian Therapeutics Inc stock as nan at the end of 2025. On May 24, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $40.
